Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure

Details for Australian Patent Application No. 2004299058 (hide)

Owner Myogen, Inc. Aventis Pharmaceutical, Inc.

Inventors Bristow, Michael; Webb, Norve; Shah, Dhiren; Domet, Jack; Jarosz, Paul; Gorczynski, Richard

Agent Pizzeys

Pub. Number AU-A-2004299058

PCT Pub. Number WO2005/058280

Priority 60/529,374 12.12.03 US

Filing date 13 December 2004

Wipo publication date 30 June 2005

International Classifications

A61K 31/415 (2006.01) - 1,2-Diazoles

A61K 9/14 (2006.01) Medicinal preparations characterised by special physical form - Particulate form, e.g. powders

Event Publications

15 June 2006 PCT application entered the National Phase

  PCT publication WO2005/058280 Priority application(s): WO2005/058280

11 September 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004299060-Modified catalyst supports

2004299057-Methods for porducing storage stable viruses and immunogenic compositions thereof